In Q1 2026 Erasca expanded its strategic alliances, signing a Clinical Trial Collaboration and Supply Agreement with Merck to combine ERAS-0015 with pembrolizumab, and a parallel CTCSA with Tango Therapeutics to pair ERAS-0015 with vopimetostat. The company also broadened its licensing deal with Joyo Pharmatech to include China, Hong Kong and Macau, and completed a $258.8 million upsized public offering in January.

April dose escalation data for ERAS-0015 monotherapy demonstrated robust response rates in KRAS G12X non-small cell lung cancer and pancreatic ductal adenocarcinoma, supported by favorable safety and tolerability with predominantly low-grade adverse events. Pharmacokinetic profiles showed dose-dependent exposure without plateau, underlining 24 mg and 32 mg once-daily dosing as recommended expansion cohorts, which began ahead of schedule alongside panitumumab combination escalation.

Erasca’s pan-KRAS inhibitor ERAS-4001 is advancing through Phase 1 dose escalation with preliminary monotherapy safety, tolerability, pharmacokinetics and early efficacy data expected in the second half of 2026. A U.S. composition-of-matter patent granted in February protects ERAS-4001 through June 2043, strengthening the program’s intellectual property position.

As of March 31, 2026, Erasca held $408.5 million in cash, cash equivalents and marketable securities, up from $341.8 million at year-end, which is projected to fund operations into the second half of 2028. Research and development expenses for the quarter totaled $27.3 million, reflecting ongoing investment in clinical programs.